everyone. good that happy but had of We solid Thanks, report morning, progress quarter financial unprecedented you another morning to were this during I'm times, speaking Antares Jack, and to for we Pharma.
Today, increase we first announced revenue of versus in quarter year. a the XX% last
as for and in seen In we well addition, by were EpiPen. sales share XYOSTED as flagship our large improvement business, These have Teva's of operations. part results demand gross strong margin market generated our we cash across generic driven product increased and in growth from an
revenue revenue products, products royalties. by marketed partner of in diverse driven X development portfolio Our is a from X and and
versus our Importantly, consisting highest and the revenue, XXX% sales, proprietary OTREXUP XYOSTED product grew period is same total which margin business, year. of last
patients. have that and X,XXX slope been Since through continue their March. prescription first XX,XXX XXX,XXX see for filled, prescriptions more prescribed last launched will before the quarter upward you #X, peaking approximately year, than trends than the physicians more Slide have XYOSTED different On in XYOSTED to product different
resets program. support to believe enhanced dealing for of prescribers and -- fill the attributed can copay increased of the card the and their prescriptions of both at XYOSTED to this annual fourth insurance of has quarter be prescriptions current from year, total growth an while copays quarter much last First enhanced We with expansion patients it made we late XX% new program sequentially writing of the and easier believe high-deductible copay XYOSTED plans.
peaking, as right pandemic COVID-XX the our and the limit to XYOSTED restrictions state, in the offices. Unfortunately, shelter-in-place prescriptions by physician patients to were ability started U.S. spread and representatives' sales began state visit
of sales that the of and by had Fortunately, already physician Once daily team XYOSTED routine commercial trained, force still an option virtual offices. their the XXXX. being which, had that entire utilized reps virtual had existing had in limited virtual into reps on to that our our all now was fourth fully trained quarter included detailing at time, OTREXUP, been our selling platform of the selling we of reps visits engaged adding
a As began were we to spread, office see reducing only. office physicians or limiting patients access hours pandemic that to
virtually. our today, of sales As entire is team operating
able detailing reps our selling visits. product are do and copay this to Armed via electronic virtual our to the with presentations samples, office get platform. tool, were They able all without cards products continue
We also virtual speaker continue to and professionals to prescribing products. our that health as information as well provide they programs able with virtual lunch need have care the been conduct learns and tools
starts patient And deployed and lower patient the of difficult. challenging challenge company a it an at sure best with on otherwise pandemic, especially our our able circumstances. patient disruption any selling in goal need for still is in context under close rapidly albeit is our tools, by we we is generate those period. the Generating very this they starts are sales dynamic to are rate the virtual Because a But minimize these at of new starts, contact staying The have to critical its making representatives products, initiating patients committed in new customers. what to to time. treatment new
testosterone XYOSTED virtually with that care. is to at of the In some fully IM patients addition safely subcutaneous If home. satisfied product of pellets. initiate way as attributes to time changing to messaging, to not authorizations With insurance product sure to visit been it be relates they once-weekly patient with implant or is in administered current or the also were a a make already prior may has and limited our testosterone switched to for had easily testosterone we communicate from a shelter-in-place injection a can an we able has physician-administered want self-administration the unique our restrictions, physicians potentially low XYOSTED, therapy, implantable appreciated an our and customers, of or injection XYOSTED. be diagnosed IM to at-home access painless to
those We starts time. in that we reasons difficult one or new perform implant injections our we of that to see pellets this patient believe the with in-office is have testosterone And switch message. targeted physicians continue
cards. refine on we as and increase to have media social messaging the continue Instagram, our through of an We and Internet copay seen Facebook utilization a in result,
learned and look in In for fact, digital. media life won we advertising, XYOSTED we since and that be is Creative branded campaign we the social When launch had creativity messy to product the weekly a prescription design the despite will Gold be recently market. data XYOSTED shipment the at our in believe COVID-XX recognition Award of continues fastest-growing total trends, Muse April prescriptions crisis. highest month testosterone on ex-factory
how pleased with COVID-XX While are impact results prescriptions, we we date. to the fully future cannot predict
states developing restrictions. is as team forward, begin for field relaxing to Going safe a return their the our plan
to We our communities we and protecting employees safety easy ensuring our XYOSTED which remain the while focused operate. in of on to our and and the customers patients continue health access to have
Turning our to first XXX,XXX Historically, According now Teva's and to the EpiPen market. in drivers, a copays Teva's share lowest to XX% and growth generic Symphony another plans. quarter, data, X seasonality the filled were Slide and has year first insurance the one with of prescriptions the due of prescription EpiPen. EpiPen of high-deductible representing of prescriptions of every resets quarter generic number
sequentially EpiPen quarter, overall almost quarter Teva's while prescriptions the in versus in increased declined total market -- share EpiPen fourth overall market during the first their period. increased the same While the XX% X%, the
is point first the that same versus last out year. market overall quarter EpiPen It important period X% to this the year, in grew also the
EpiPen, first COVID-XX results quarter. Teva's impact been do very While sales know pleased may fully not how the of the we through with generic we've
pipeline our X. now Turning Slide to on
approved Let's begin version year. According believe this generic filing Teva's of ANDA with Teva, the part could Forteo. in to they be of their latter
at Forteo reminder, have a status. pharmacy, generic be will fully expects and they first-to-file the maintain their they substitutable As Teva pen
achieved total. to that billion million in XXXX sales, $X.X Lilly's global XX-K, Forteo with of up $XXX According making the U.S.
significant Teva high with provides margin cost-plus sell for agreement us digit single both If a for and the approved, Our Teva from percentages. opportunity devices at the royalties represents to receive product mid-teen escalating we believe Antares. to and
quantities a manufactured already reminder, and of generic devices we As shipped Teva. have to prelaunch Forteo
to Pharmaceuticals entered exciting a self-administered program To with completed selatogrel, #X. which studies pen, the new believe stop a Last heart significant collaboration symptoms the Idorsia auto attack. X new is Phase next in our rescue our a is combining Slide product new on could to detailed we pipeline with selatogrel a into has QuickShot chemical November, The injector. be onset suspected Idorsia at II of entity and date, develop selatogrel
will this labeled finished then global our clinical It partner the authorities. responsible reliability as while product with then finalizing for first device, of global design provide product, global registration cost-plus will and product. in the and will the of development be and Antares entitled pending Antares of will as the study the studies The believe at margin, We initiated and that conducts fully usability partner health QuickShot and of commercialization to bridging have foreign a study a importance global with Phase on patients, well receive initiated approval. FDA regulatory be the assembled product, Idorsia escalating responsible be the for significant. for of rescue study We approvals product. the royalties potential for both pay to the obtaining be half for commercial expected be Idorsia XXXX. to can pen sales is net will III
with Turning Pfizer. our to development now agreement
We for pen. the rescue progress continue to good an make on undisclosed program
mid-single the will to with on we commercial-ready subject FDA reminder, margin then digit a approval, cost-plus and a escalating receive product from of packaged double-digit percentages As fully end at Pfizer product. royalties sales to supply
the line on from Pfizer. received estimates once time we've development clearance provide will We
finally, the operate and made pandemic, to facing. the supply response most of as to global health development, changes way staff In care number And the and company COVID-XX of we limited like functions the are such we we are executive functions manufacturing a the of essential I'd all our given as in crisis remotely, those have for outline chain. some necessary we to have administrative our working to facilities and
we utilizing for customers delivering to virtual on other immune provides and employees now field-based this As new who medicines existing our suspended media with partners patients, potential Antares and health social we and platforms our important care professionals. to forms of mission. discussed committed for our essential and and are activity earlier, face-to-face are connect
any for mitigate potential to We are to working have COVID-XX and a order a in and and closely partners customers our pandemic. with Thus our manage ability disruptions April. our manufacturers softening and our to far, our of end distributors the chain demand of the third-party products limited March we through supply of into products to supply as seen result activities
our treat growth. with of that we portfolio navigate life-threatening a chronic situated strong commercial key this With are objectives coupled execute financial long-term diseases, well our to position, and on through support pandemic products that we strategic and to believe
I to turn first over for Fred call financial will on quarter. Fred? the details now the our
